Cetuximab in combination with chemotherapy for patients with gastrointestinal cancer / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 385-388, 2008.
Article
in Chinese
| WPRIM
| ID: wpr-357416
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the efficacy and safety of cetuximab in combination with chemotherapy for gastrointestinal cancers.</p><p><b>METHODS</b>The data of 35 colorectal cancers (CRC), 11 advanced gastric cancers (AGC) and 3 other gastrointestinal cancers treated with cetuximab in combination with chemotherapy were retrospectively reviewed, and the efficacy and adverse events were analyzed.</p><p><b>RESULTS</b>Of the 49 patients, 37 were evaluable. Twenty-nine CRC were evaluated by RECIST criteria with a PR rate of 24.1%, SD rate of 51.8% and disease control rate (DC) of 75.9%. Subgroup analysis showed that the response rate (RR) and DC rate were 36.4% and 90.9% for the first-line therapy, 20.0% and 70.0% for the second-line therapy, 12.5% and 62.5% in the heavily pre-treated cases, respectively. Six patients with AGC were assessed for efficacy, including 2 PR for first-line therapy, 1 CR and 1 SD for second-line therapy, and 2 with progressive disease in the heavily pre-treated cases. Rash was observed in 79.6% of the patients with a grade 3 rate of 8.2%, and the severity was relevant to the DC. Grade 3 or 4 neutropenia was observed in 16.3%, and grade 3 infusion related reaction (IRR) happened in 4.1% (2 cases).</p><p><b>CONCLUSION</b>Cetuximab combined with chemotherapy is safe and effective for patients with gastrointestinal cancer. In colorectal cancers, the combination therapy shows a high disease control rate, especially in first-line therapy. The severity of rash may be parallel with efficacy. The combination therapy is also promising in the treatment of AGC.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Stomach Neoplasms
/
Remission Induction
/
Colorectal Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
/
Retrospective Studies
/
Follow-Up Studies
/
Combined Modality Therapy
/
Therapeutic Uses
/
Drug Therapy
/
Exanthema
Type of study:
Observational study
/
Prognostic study
/
Risk factors
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
Language:
Chinese
Journal:
Chinese Journal of Oncology
Year:
2008
Type:
Article
Similar
MEDLINE
...
LILACS
LIS